Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Beeline Medicines Corporation
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed ≥ 12 weeks before the screening visit and qualify as having SLE according to the SLE International Collaborating Clinics (SLICC) Classification Criteria at the screening visit
Test positive, as determined by the central laboratory, for at least one of the following lupus related autoantibodies at the time of screening: antinuclear antibody ≥ 1:80, anti-double-stranded deoxyribonucleic acid (dsDNA) antibody, or anti-Smith antibody.
Have a total Hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score ≥ 6 points and clinical Hybrid SLEDAI score ≥ 4 points with joint involvement and/or rash
You may not be if
Active severe lupus nephritis (LN) as assessed by the investigator
Active or unstable neuropsychiatric lupus manifestations defined by the Hybrid SLEDAI
Diagnosis of Mixed Connective Tissue Disease for which the predominant diagnosis is not SLE
Antiphospholipid Syndrome
Clareo Health | A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
